Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. reports developments in women's health diagnostics, with news centered on its PreTRM® Test for spontaneous preterm birth risk prediction in asymptomatic singleton pregnancies. The company uses proteomics, bioinformatics and pregnancy biomarker information to support maternal and neonatal health.
Recurring updates include financial results, commercial adoption and payer engagement for PreTRM, clinical evidence from the PRIME study and related publications, investor presentations, healthcare conference activity, capital allocation and financing actions supporting commercialization.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sera Prognostics (NASDAQ: SERA), focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information, will report its first-quarter fiscal 2023 financial results on May 10, 2023. The report will follow a conference call at 5:00 PM ET, where operational highlights and financial results will be discussed. The PreTRM® Test, developed by Sera, predicts preterm birth risk, allowing for early interventions and potentially reducing healthcare costs associated with complications. The firm emphasizes its commitment to improving pregnancy care and health outcomes for mothers and newborns, while navigating various risks related to its revenue reliance on the PreTRM Test and potential market competition.
Sera Prognostics, focused on maternal and neonatal health, reported its financial results for Q4 and full year 2022.
Q4 revenue increased to $65,000, up from $26,000 in Q4 2021. Full-year 2022 revenue reached $268,000, compared to $82,000 in 2021. Total operating expenses decreased to $10.5 million in Q4, down from $12.6 million in Q4 2021; however, full-year expenses rose to $45.9 million, up from $35.5 million.
The net loss for Q4 was $9.7 million, improved from $12.5 million the previous year. The company ended 2022 with approximately $104 million in cash and equivalents.
Sera Prognostics, Inc. (NASDAQ: SERA) will report its fourth quarter and full year 2022 financial results on March 22, 2023, after market close. A conference call to discuss the results will follow at 5:00 p.m. Eastern Time. The company is dedicated to improving maternal and neonatal health with its innovative pregnancy biomarker solutions, including the PreTRM® Test that predicts preterm birth risk. Sera's operational focus aims to enhance pregnancy care and reduce healthcare costs associated with complications from preterm births, which carry significant financial burdens estimated at $25 billion annually in the U.S.
Sera Prognostics, known as The Pregnancy Company (NASDAQ: SERA), announced its participation in two significant upcoming healthcare conferences: the Cowen Health Care Conference in Boston from March 6-8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference virtually from March 13-15, 2023. CEO Gregory C. Critchfield will provide updates on the company's progress, including its innovative PreTRM® Test, which aids in predicting preterm birth risk. Both conferences will feature live webcasts available on the company's investor page, ensuring accessible information for stakeholders.
Sera Prognostics (NASDAQ: SERA) announced positive top-line results from the AVERT PRETERM TRIAL, showcasing significant improvements in neonatal health outcomes and reduced hospitalization duration. The study involved 1,453 expectant mothers and demonstrated statistically significant reductions in severe neonatal morbidity and mortality. Both primary outcomes were met, affirming the effectiveness of the PreTRM® test-and-treat strategy. These results build upon previous studies and support ongoing trials, including the large PRIME study. The PreTRM® Test provides crucial risk assessments for spontaneous preterm birth, aiming to enhance outcomes for mothers and infants.
Sera Prognostics (NASDAQ: SERA) partners with Fors Marsh to introduce the PreTRM® Test as part of employee maternity benefits, effective January 1, 2023. This innovative blood-based test provides early risk assessments for spontaneous preterm births, identifying nearly 90% of at-risk pregnancies. Fors Marsh aims to enhance workforce health and cut maternity costs through this offering. Sera asserts that the PreTRM® Test's predictive capabilities contribute significantly to improving maternal and neonatal health outcomes.